Vanesa Longobardi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vanesa Longobardi has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- María Belén Zanchetta
Instituto de Investigaciones Metabólicas, Universidad del Salvador, Buenos Aires, Argentina
3 shared publications - Edgardo Smecuol
Small Bowel Section, Department of Medicine, Hospital de Gastroenterología Dr Carlos Bonorino Udaondo,Buenos Aires,Argentina
2 shared publications - Eduardo Mauriño
Small Intestine Section, Department of Medicine, Hospital de Gastroenterología “Dr. Carlos Bonorino Udaondo”, Buenos Aires, Argentina
2 shared publications Horacio Vázquez
2 shared publicationsJulio C. Bai
2 shared publicationsMaría Laura Moreno
2 shared publications
Latest Publications
- 10 August 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 272
“Acute-phase reactions to zoledronate in clinical practice: a prospective single center study of 1,150 patients.”
- 10 August 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 272
“Acute-phase reactions to zoledronate in clinical practice: a prospective single center study of 1,150 patients.”
- Open Access
- 30 April 2024
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 8 (6) , ziae044
Three-year effect of bisphosphonates on bone mineral density after denosumab withdrawal: observations from a real-world study
Data on long-term treatment regimens for preventing bone mineral density (BMD) loss that occurs after denosumab (Dmab) withdrawal are scarce. Our aim was to evaluate the long-term changes (12–36 months) in BMD and bone turnover markers in a group of postmenopausal women who had been treated with Dmab and received subsequent treatment with bisphosphonates. Secondary objectives were to evaluate factors associated with BMD loss, to compare the BMD change in patients who received oral vs intravenous bisphosphonates, and to assess the frequency of fragility fractures after Dmab discontinuation. The clinical data of 54 patients, 26 of whom had clinical and DXA assessments at 36 months, were analyzed. After 12 months, the mean LS BMD had decreased by 2.8% (±5.0), FN BMD by 1.9% (±5.8), and TH BMD by 1.9% (±3.7). After 36 months, LS BMD had decreased by 3.7% (±6.7), FN BMD by 2.5% (±7.1), and TH BMD by 3.6% (±5.2). C-terminal cross-linked telopeptide of type I collagen significantly increased during the first 12 months after Dmab withdrawal but then decreased at 36 months. BMD loss at 12 months was higher in patients with more than 30 months of Dmab treatment, but this difference was only statistically significant at FN (−3.3% vs −0.3%, P = .252 at LS, −3.3% vs 0.3%, P = .033 at FN, and −2.1% vs 0.9, P = .091 at TH). There were no statistically significant differences regarding the change in BMD at 12 and 36 months between oral and intravenous treatment. Seven patients suffered incidental vertebral fractures (clinical vertebral fractures: n = 6, morphometric fractures: n = 1) three of which were multiple. None of these patients were treated following international or institutional guidelines or recommendations. In summary, our study suggests that bisphosphonates can help maintain BMD for 36 months after Dmab discontinuation. In our real-life study, we examined 54 patients who received bisphosphonate treatment after stopping denosumab. Among them, 26 patients underwent long-term assessments. We found that after three years of sequential treatment with bisphosphonates, bone density loss was less than 4%, with most of the loss occurring within the first 12 months. This suggests that bisphosphonates can help maintain bone density in patients who discontinue denosumab.
- 30 April 2024
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 8 (6) , ziae044
Open AccessThree-year effect of bisphosphonates on bone mineral density after denosumab withdrawal: observations from a real-world study
Data on long-term treatment regimens for preventing bone mineral density (BMD) loss that occurs after denosumab (Dmab) withdrawal are scarce. Our aim was to evaluate the long-term changes (12–36 months) in BMD and bone turnover markers in a group of postmenopausal women who had been treated with Dmab and received subsequent treatment with bisphosphonates. Secondary objectives were to evaluate factors associated with BMD loss, to compare the BMD change in patients who received oral vs intravenous bisphosphonates, and to assess the frequency of fragility fractures after Dmab discontinuation. The clinical data of 54 patients, 26 of whom had clinical and DXA assessments at 36 months, were analyzed. After 12 months, the mean LS BMD had decreased by 2.8% (±5.0), FN BMD by 1.9% (±5.8), and TH BMD by 1.9% (±3.7). After 36 months, LS BMD had decreased by 3.7% (±6.7), FN BMD by 2.5% (±7.1), and TH BMD by 3.6% (±5.2). C-terminal cross-linked telopeptide of type I collagen significantly increased during the first 12 months after Dmab withdrawal but then decreased at 36 months. BMD loss at 12 months was higher in patients with more than 30 months of Dmab treatment, but this difference was only statistically significant at FN (−3.3% vs −0.3%, P = .252 at LS, −3.3% vs 0.3%, P = .033 at FN, and −2.1% vs 0.9, P = .091 at TH). There were no statistically significant differences regarding the change in BMD at 12 and 36 months between oral and intravenous treatment. Seven patients suffered incidental vertebral fractures (clinical vertebral fractures: n = 6, morphometric fractures: n = 1) three of which were multiple. None of these patients were treated following international or institutional guidelines or recommendations. In summary, our study suggests that bisphosphonates can help maintain BMD for 36 months after Dmab discontinuation. In our real-life study, we examined 54 patients who received bisphosphonate treatment after stopping denosumab. Among them, 26 patients underwent long-term assessments. We found that after three years of sequential treatment with bisphosphonates, bone density loss was less than 4%, with most of the loss occurring within the first 12 months. This suggests that bisphosphonates can help maintain bone density in patients who discontinue denosumab.
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S267
Long-Term Improvement of Impaired Bone Microarchitecture in Patients with Celiac Disease on a Gluten-Free Diet. A Prospective Longitudinal Study
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S267
Long-Term Improvement of Impaired Bone Microarchitecture in Patients with Celiac Disease on a Gluten-Free Diet. A Prospective Longitudinal Study
- 13 February 2016
- Published by Springer Nature in Current Osteoporosis Reports
- Vol. 14 (2) , 43-48
Bone and Celiac Disease
More than 50 % of untreated patients with celiac disease (CD) have bone loss detected by bone densitometry (dual-energy X-ray absorptiometry:DXA). Moreover, patients with CD are more likely to have osteoporosis and fragility fractures, especially of the distal radius. Although still controversial, we recommend DXA screening in all celiac disease patients, particularly in those with symptomatic CD at diagnosis and in those who present risk factors for fracture such as older age, menopausal status, previous fracture history, and familial hip fracture history. Bone microarchitecture, especially the trabecular network, may be deteriorated, explaining the higher fracture risk in these patients. Adequate calcium and vitamin D supplementation are also recommended to optimize bone recovery, especially during the first years of gluten free diet (GFD). If higher fracture risk persists after 1 or 2 years of GFD, specific osteoactive treatment may be necessary to improve bone health.
- 13 February 2016
- Published by Springer Nature in Current Osteoporosis Reports
- Vol. 14 (2) , 43-48
Bone and Celiac Disease
More than 50 % of untreated patients with celiac disease (CD) have bone loss detected by bone densitometry (dual-energy X-ray absorptiometry:DXA). Moreover, patients with CD are more likely to have osteoporosis and fragility fractures, especially of the distal radius. Although still controversial, we recommend DXA screening in all celiac disease patients, particularly in those with symptomatic CD at diagnosis and in those who present risk factors for fracture such as older age, menopausal status, previous fracture history, and familial hip fracture history. Bone microarchitecture, especially the trabecular network, may be deteriorated, explaining the higher fracture risk in these patients. Adequate calcium and vitamin D supplementation are also recommended to optimize bone recovery, especially during the first years of gluten free diet (GFD). If higher fracture risk persists after 1 or 2 years of GFD, specific osteoactive treatment may be necessary to improve bone health.